Research Use Only - Not for human consumption. 18+ only.

Melanotan II vs Melanotan I

Evidence-based comparison · Updated 2026

Summary

Melanotan I (afamelanotide) is the clinically validated option, FDA-approved for erythropoietic protoporphyria with strong evidence for photoprotection and melanogenesis. Melanotan II carries additional effects on libido and appetite suppression but has broader receptor activity, more systemic side effects, and remains research-only. For medical photoprotection, Melanotan I is the clear choice; Melanotan II is explored in research contexts where its broader melanocortin activity is the focus.

Side-by-Side Comparison

Melanotan IIMelanotan I
EvidenceCGrade CPrimarily animal or in-vitro studies; limited human dataAGrade ALarge human randomised controlled trials or FDA/major-authority approved
RegulatoryResearch OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use onlyFDA ApprovedFDA ApprovedApproved by the US Food and Drug Administration for at least one indication
Benefits
  • +Stimulates melanogenesis (tanning)
  • +Tanning without UV exposure (photoprotection)
  • +Appetite suppression
  • +Libido enhancement
  • +May reduce sun damage risk
  • +Induces skin pigmentation and tanning
  • +Provides photoprotection against UV damage
  • +Reduces photosensitivity in erythropoietic protoporphyria
  • +Melanocortin receptor agonist activity
  • +Fewer systemic side effects than Melanotan II
Dosage250-500 mcg mcg — Daily until desired tan, then 2-3x/week maintenance0.5-1 mg — 1x daily
RouteSubcutaneousSubcutaneous
CategoryTanning & PigmentationTanning & Pigmentation

Full research page

Melanotan II →

Full research page

Melanotan I →

Which Should You Choose?

Melanotan I is a selective MC1R agonist, confining its activity primarily to melanocytes and photoprotective pathways. Melanotan II binds non-selectively across multiple melanocortin receptor subtypes (MC1R through MC5R), which accounts for both its broader effect profile and its higher incidence of systemic side effects.

Choose Melanotan II when:

  • +You require an FDA-approved, clinically validated option for a diagnosed photosensitivity condition such as erythropoietic protoporphyria
  • +Minimizing systemic side effects is a priority, given its selective MC1R binding limits off-target receptor activity
  • +The primary research or treatment goal is photoprotection and eumelanin upregulation without secondary effects on sexual function or appetite

Choose Melanotan I when:

  • +The research focus encompasses multiple melanocortin-mediated pathways simultaneously, including appetite regulation and sexual function alongside tanning
  • +The study design specifically requires a non-selective melanocortin agonist to observe comparative receptor activation across MC1R-MC5R
  • +Libido enhancement or appetite suppression are explicit secondary endpoints in a preclinical or approved research protocol

Stacking Melanotan I and Melanotan II is not a documented or rationally supported research practice, as both target overlapping MC1R pathways, creating redundant receptor stimulation without additive benefit and with compounded risk of side effects.

Frequently Asked Questions

Does Melanotan II produce faster or darker tanning results than Melanotan I?⌄
Direct head-to-head clinical trials comparing tanning speed and depth are limited. Melanotan II has been reported in small studies to produce rapid pigmentation changes, which may relate to its broader receptor binding rather than superior MC1R potency alone. Melanotan I (afamelanotide) demonstrates consistent, clinically documented eumelanin increases through its selective MC1R mechanism. Neither compound has been rigorously compared in a controlled trial designed specifically to measure tanning magnitude or onset speed.
How do the side effect profiles of Melanotan I and Melanotan II differ?⌄
Melanotan I's selective MC1R activity generally restricts side effects to mild flushing, nausea, and injection site reactions, as observed in clinical trials for erythropoietic protoporphyria. Melanotan II, due to its non-selective binding across MC3R, MC4R, and MC5R, is associated with additional systemic effects including spontaneous erections, significant nausea, yawning, and more pronounced cardiovascular responses. The broader receptor activation profile of Melanotan II is the primary driver of this expanded side effect burden.
Can either Melanotan I or Melanotan II be used without UV exposure to achieve tanning?⌄
Both peptides can stimulate melanin synthesis independent of UV radiation by activating MC1R on melanocytes and upregulating tyrosinase activity. Melanotan I's clinical data confirm photoprotective eumelanin increases without mandatory UV exposure, as demonstrated in EPP patients. Melanotan II has also been reported in research settings to induce pigmentation without UV priming. However, the depth and quality of UV-independent pigmentation may vary, and this use remains outside any approved clinical indication for both compounds except Melanotan I's specific EPP approval.
Which peptide is the better choice for a researcher studying photoprotection mechanisms specifically?⌄
For researchers focused exclusively on photoprotection pathways, Melanotan I (afamelanotide) is the more appropriate tool due to its selective MC1R agonism, well-characterized mechanism involving eumelanin upregulation and reduction of UV-induced DNA damage, and a robust body of Phase II and Phase III clinical data. Its selectivity reduces confounding from off-target receptor activity, making it easier to isolate photoprotective outcomes. Melanotan II introduces variables from MC3R-MC5R activity that complicate interpretation in studies narrowly designed around UV protection endpoints.

Not sure which fits your research goals?

Use the Goal Finder

Answer 3 questions and get a personalised peptide recommendation ranked by evidence grade.

Find My Peptide →

More Comparisons

bpc 157 vs tb 500mots c vs semaglutidedsip vs melanotan iiretatrutide vs tirzepatidecjc 1295 vs ipamorelin